Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Суббота, 20 декабря 2008 г.
Сделать стартовойДобавить в избранноеСообщить о странице другуW@PAvantGoPDA
В стремлении к прогрессу, с заботой о людях
Дюфастон
Регистрация

Библиография

Включен в программу ОНЛС

  1. Van Amsterdam PH, Overmars H, Scherpenisse PM, et al. Dydrogesterone: metabolism in man. Eur J Drug Metab Pharmacokin 1980; 5(3): 173-184
  2. Jager FC, Michielsens PMLJ, Minter, et al. Summary of the properties of dydrogesterone. Solvay Report H. 102.053, 1988
  3. Sturdee DW. Hormone replacement therapy: the benefits and risks. Prescr J 1994: 34: 234-242
  4. Barlow DH, Brockie JA, Rees CMP. Study of general practice consultations and menopausal problems. Br Med J 1991; 302: 274-276
  5. Lufkin EG, Wahner HW, O'FaIlon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 1992; 117: 1-9
  6. Amy JJ. Femoston®: Effects on bone and quality-of-life. Eur Menopause J 1995; 2 (4, suppl): 16-22
  7. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195-1198
  8. Barlow DH. Department of Health Advisory Group on Osteoporosis Report. November 1994.
  9. Stampfer MJ. Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63
  10. Crook D, Godsland IF. Stevenson JC. The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: a review. Eur Menopause J 1995; 2 (4, suppl): 23-30
  11. Whitehead M, Godfree V. 'Hormone replacement therapy: Your questions answered.' London: Churchill Livingstone, 1992
  12. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham study. Ann Intern Med 1978; 89: 157-161
  13. Spector TD. Use of estrogen replacement therapy in high risk groups in the United Kingdom. Br Med J 1989; 299: 1434-1435
  14. Sinclair KK, Bond CM, Taylor RJ. Hormone replacement therapy; a study of women's knowledge and attitudes. Br J Gen Pract 1993; 43:365-370
  15. Roberts PJ. The menopause and hormone replacement therapy: views of women in general practice receiving hormone replacement therapy. Br J Gen Pract 1991: 41:421-434
  16. Stumpf PG. Pharmacokinetics of estrogen. Obstet Gynecol 1990;75: 9S-14S
  17. Coope J, Thomson JM, Poller L. Effects of 'natural estrogen' replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975; 4: 139-143
  18. Hunt K, Vessey M. The risks and benefits of hormone replacement therapy. Curr Obstet Gynaecol 1991; 1: 21-27
  19. Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. Br Med J 1991:302:1317-1320
  20. Campbell S. Whitehead M. Estrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977; 4: 31-47
  21. Archer DF, Fischer LA, Rich D, et al. Estrace vs Premarin for treatment of menopausal symptoms: Dosage comparison study. Adv Therapy 1992:9: 21-31
  22. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. Br Med J 1993; 307: 836-840
  23. Quigley MET, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987;156:1516-1523
  24. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650
  25. Kanis JA, lohnell 0, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 1992; 305: 1124-1128
  26. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317(19): 1169-1174
  27. Marx CW, Dailey GB, Cheney C, et al. Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Min Res 1992; 7(11): 1275-1279
  28. De Cleyn K, Buytaert P, Delbeke L, Gerris J. Equine estrogen-dydrogesterone therapy in the management of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1986:23:201-209
  29. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993; 153: 1201-1209
  30. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use oestrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation 1987,75: 1102-1109
  31. Stampfer MJ. Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63
  32. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988: 159: 312-317
  33. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080-1086
  34. Gambrell RD. Prevention of endometrial cancer with progestogens. Maturitas 1986; 8: 159-168
  35. Burch DJ, Spowart KJM, Jesinger DK, et al. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17b- estradiol. Br J Obstet Gynaecol 1995; 102: 243-248
  36. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined estradiol and dydrogesterone. Obstet Gynecol (submitted)
  37. Van der Mooren MJ, Hanselaar AGJM, Bonn GF, Rolland R. Changes in the withdrawal bleeding pattern and endometrial histology during 17b-estradiol - dydrogesterone therapy in postmenopausal women: a 2 year prospective study. Maturitas 1995; 20: 175-180
  38. Bergeron C. Summary of combined data on endometrial safety considering the endpoint hyperplasia in postmenopausal women taking sequential, combined estradiol and dydrogesterone (Femoston). 8th Int Congr on the Menopause, Sydney, 1996 (Abstract)
  39. Al-Azzawi F, Habiba M. Regular bleeding on hormone replacement therapy: a myth? Br J Obstet Gynaecol 1994; 101: 661 -662
  40. Gelfand M, Fugere P, Wiita B. Young H, Lorrain J, Ferenczy A. A double-blind comparison of oral conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women. Submitted for publication.
  41. Lippuner K, Hanggi W, Birkhauser MH, Jaeger Ph. Prevention of postmenopausal osteoporosis in a comparative study with tibolone, oral estradiol and transdermal estradiol. 1996; World Congress on Osteoporosis, Amsterdam (Abstract)
  42. Lees B, Pugh M, Siddle N, Stevenson JC. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy Osteoporosis Int 1995; 5: 344-348
  43. Voetberg GA, Netelenbos JC, Kenemans P, et al. Estrogen replacement therapy combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994; 79:1465-1469
  44. Verhaar HJJ, Damen CA, Duursma SA, Scheven BAA. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone 1994; 15(3): 307-311
  45. van Hoof HJC. van der Mooren MJ, Swinkels LMJW, et al. Hormone replacement therapy increases serum 1,25-dihydroxyvitamin D: a 2-year prospective study. Calcif Tissue Int 1994; 55: 417-419
  46. Crook D, Stevenson IC, Siddle NC. Dydrogesterone fails to oppose the effects of estrogen on serum lipoprotein metabolism, 7th International Congress, Menopause; 1993 Jun 20-24; Stockholm: Abstract 260
  47. Ottosson UB, Johansson BG, von Schouiz B. Subtractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. J Obst Gynecol 1985:151: 746-750
  48. Gelfand M, Fugere P, Bissonnette F. Cardiovascular risk factors during sequentially combined 17b oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women. Submitted for publication.
  49. van der Mooren MJ, Demacker PNM, Thomas CMG, et al. A 2-year study on the beneficial effects of 17b-estradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynaecol Reprod Biol 1993:52: 117-123
  50. Stevenson JC, Proudler AJ, Walton C, Godsland IF HRT mechanisms of action: carbohydrates. Int J fertil 1994; 39 (Suppl 1): 50-55
  51. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993: 42(7): 846-853
  52. Gaspard UJ, Wery D, Herman Ph, et al. Carbohydrate metabolism is not impaired in postmenopausal women using micronised estradiol and dydrogesterone for twelve months, 7th International Congress, Menopause; 1993 Jun 20-24; Stockholm: Abstract 260
  53. Gaspard UJ, Gottal J-M, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995; 21: 171-178
  54. Van der Mooren MJ, Wouters MGAJ, Blom HI, et al. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733-736
  55. Data on file, Solvay Report H102.901.MC
  56. Campagnoli C, Lesca L, Cantamessa C, Peris C. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings. Maturitas 1993; 18:21-46
  57. Kuhl H. Pharmacokinetics of estrogens and progestogens. Maturitas 1990; 12: 171-197
  58. Howell A, Bundred N, Evans G, Anderson E. 'Should I take HRT, doctor?': Hormone replacement therapy in women at increased risk of increased breast cancer and in survivors of the disease. J Br Men Soc 1995; 1(2):9-17
  59. International Medical Benefit/Risk Foundation Workshop. Hormone replacement therapy (HRT) and breast cancer risk. Pharmaco-epidemiol Drug Saf 1993; 2: 103-105
  60. Massil H, O'Brien PMS. Premenstrual syndrome. Br Med J 1986; 293: 1289-1292
  61. Bancroft J, Backstrom T. Premenstrual syndrome. Clin Endocrinol 1985; 22: 313-336
  62. Day JB. Clinical trials in the premenstrual syndrome. Curr Med Res Opin 1979; 6 (Suppl. 5): 40-45
  63. Kerr GD, Day JB, Munday MR, et al. Dydrogesterone in the treatment of the premenstrual syndrome. Practitioner 1980; 224: 852-855
  64. Haspels AA. Proceedings of a Workshop on Premenstrual Syndrome: VIth International Congress of Psychosomatic Obstetrics and Gynecology, Berlin, 1980: 81-92
  65. Smith RNJ, Studd JWW, Zamblera D. Holland EFN. A randomised comparison over 8 months of 100mg and 200mg twice weekly doses of transdermal estradiol in the treatment of severe premenstrual syndrome. Br I Obst Gynaecol 1995: 102: 475-484
  66. Ohlenroth G, Hatzmann W. Die therapie der juvenilen dysmenorrho mit 6-dehydro-retro-progesteron. Med Welt 1982; 33: 645-646
  67. West CP. Dysfunctional uterine bleeding. Prescr J 1994; 34: 215-220
  68. Belaisch J. Metrorragies et desir de grossesse. ConcMedicale 1991 (September): 880
  69. Eiholzer U. L'adolescente et 1'amenorrhee secondaire. Rev Med Suisse Romande 1995; 115:609-612
  70. Schweppe KW. Recent Advances in the Management of Endometriosis, ed Rock JA & Schweppe KW. Parthenon 1988: 13-30
  71. Johnston WIH. Dydrogesterone and endometriosis. Br J Obstet Gynaecol 1976; 83: 77-80
  72. Walker SM. The treatment of endometriosis with dydrogesterone. Br J Clin Pract 1983; Suppl. 24: 40-46
  73. Wiegerinck MAHM, Van Dop PA, Brosens IA. The staging of peritoneal endometriosis by the type of active lesion in addition to the revised American Fertility Society classification. Fertil Steril 1993:60:461-464
  74. Overton CE, Lindsay PC, Johal B, et al. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril 1994:62:701-707
  75. Rothe K. Gestagene und corpus-luteum-insuffizienz. Zentralbl Gynakol 1995; 117: 2-5
  76. Belaisch-Allart J, Testart J, Fries N, et al. The effect of dydrogesterone in supplementation in an IVF programme. Human Reprod 1987; 2: 183-185
  77. Bishop PMF, Borell U, Diczfalusy E, Tillinger K-G. Effect of dydrogesterone on human endometrium and ovarian activity. Acta Endocrinol 1962; 40: 203-216
  78. Ullery JC, De Neef JC, Holzaepfel JH. Dydrogesterone therapy: clinical observations and laboratory findings in 61 patients. Obstet Gynecol 1963; 22: 38-45
  79. Netter A, Yaneva H, Salomon-Bernard Y. Notre experience clinique de la dydrogesterone. Comptes Rendus Soc Fr Gynecol1962;5:1-7
  80. Oddens BJ, Boulet MJ, Lehert P, Visser AP. A study on the use of medication for climacteric complaints in Western Europe-II. Maturitas 1994; 19: 1-12
  81. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17b-oestradiol: effects on serum lipoproteins and glucose tolerance. Submitted for publication.
  82. Miller VT, Muesing RA, LaRosa JC et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol 1991; 77(2): 235-240



Solvay Pharma Реклама: Таденан! Лечение доброкачественной гиперплазии предстательной железы!
Баннерная сеть Солвей-Фарма.ру
Адрес


Последнее обновление  20.12.2008 г.